10-Q quarterly report · filed Nov 13, 2026

Jade Biosciences, Inc. (JBIO) Q3 2026 10-Q Quarterly Report

Short answer

Jade Biosciences, Inc. (JBIO) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$35M
−39.2% YoY · +37.1% QoQ
EPS (diluted)
−$0.39
−205.4% YoY · +48.7% QoQ

Source: XBRL data from the Jade Biosciences, Inc. (JBIO) Q3 2026 10-Q on SEC EDGAR. USD.

Jade Biosciences, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • Net loss $35.1M vs $25.2M YoY, operating margin not applicable due to no revenue
  • JADE101 R&D $12.1M vs $6.0M, strongest program; JADE201 $3.5M vs $6.7M, weakest
  • Cash and investments $475.7M, operating cash use $96.6M for nine months
  • June offering net proceeds $161.6M, management expects funding for at least twelve months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Jade Biosciences, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.